Royalty Pharma (RPRX): Officer sold ~$932K
Marshall Urist, Officer at Royalty Pharma, sold ~$932K of Royalty Pharma shares.
- ~$932K
- Approx. value · 23K sh @ $39.93
- 183K
- Holds after · shares reported
- Traded
- Dec 1, 2025
- Filed
- Dec 4, 2025
What stands out in this filing
- The sale was 11.3% of the shares this insider held before it; the filing reports 183,334 shares, held indirectly afterwards.
- 23,333 shares at an average of $39.93 each, as reported on the form.
- Footnote references a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 17, 2025Insider · 1 personInsiders: 2 sales (~$2.7M)
- Nov 19, 2025Insider · 1 personInsiders: 8 sales (~$5.2M)
- Nov 24, 2025Insider · 1 personInsiders: 4 sales (~$2.7M)
- Dec 1, 2025 · this disclosureInsiderOfficer sold ~$932K of RPRX shares in the open market
What came next
- Dec 1, 2025Insider · 2 peopleInsiders: 3 sales (~$3.5M)
- Dec 3, 2025InsiderOfficer sold ~$4.38M of RPRX shares in the open market
- Dec 5, 2025Insider · 1 personInsiders: 2 sales (~$1.6M)
- Dec 15, 2025Insider · 1 personInsiders: 2 sales (~$2.7M)
- Dec 16, 2025InsiderOfficer sold ~$766K of RPRX shares in the open market
- Dec 17, 2025InsiderOfficer sold ~$3.06M of RPRX shares in the open market
- Dec 18, 2025InsiderOfficer sold ~$1.18M of RPRX shares in the open market
- Dec 19, 2025InsiderOfficer sold ~$768K of RPRX shares in the open market
- Dec 20, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 20, 2025, George W. Lloyd, age 66, informed Royalty Pharma plc (the “Company”) of his decision to transition from his role of Executive Vice President and Chief Legal Officer effective December 31, 2025.”
- Dec 26, 2025InsiderOfficer sold ~$786K of RPRX shares in the open market
- Jan 2, 2026Insider · 2 peopleInsiders: 3 sales (~$3.4M)
- Jan 9, 2026InsiderOfficer sold ~$816K of RPRX shares in the open market
- Jan 16, 2026InsiderOfficer sold ~$790K of RPRX shares in the open market
- Jan 20, 2026Insider · 1 personInsiders: 2 sales (~$2.7M)
- Jan 23, 2026InsiderOfficer sold ~$805K of RPRX shares in the open market
- Jan 30, 2026InsiderOfficer sold ~$822K of RPRX shares in the open market
- Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$4.6M)
- Feb 3, 2026Insider · 1 personInsiders: 2 sales (~$4.9M)
- Feb 4, 2026Insider · 1 personInsiders: 2 sales (~$873K)
- Feb 11, 2026Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Royalty Pharma
For Royalty Pharma, OQRO holds 16 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RPRX page.
Other recent filings by Marshall Urist, EVP, Research & Investments
- SEC Form 4 at Royalty Pharma (RPRX)Nov 18, 2026
- SEC Form 4 at Royalty Pharma (RPRX)Nov 18, 2026
- SEC Form 4 at Royalty Pharma (RPRX)Oct 6, 2026
- SEC Form 4 at Royalty Pharma (RPRX)Oct 1, 2026
- SEC Form 4 at Royalty Pharma (RPRX)Jul 3, 2026
The full history of Marshall Urist, EVP, Research & Investments is on the profile page.
How this filing works
Explore the data
Common questions
Which Royalty Pharma (RPRX) insider traded, and how much?
Marshall Urist, Officer at Royalty Pharma, sold ~$932K of Royalty Pharma shares. 23K shares at $39.93.
When did it happen, and when was it made public?
Traded: Dec 1, 2025. Filed: Dec 4, 2025. That is 3 days between the two dates.
What stands out in this filing?
The sale was 11.3% of the shares this insider held before it; the filing reports 183,334 shares, held indirectly afterwards. 23,333 shares at an average of $39.93 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Royalty Pharma recently?
For Royalty Pharma, OQRO holds 16 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the RPRX page.
Does this mean RPRX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Royalty Pharma
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
Everything OQRO holds on this company is on its RPRX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
